Companies › Vividion Therapeutics
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VVD-133214 WRN protein inhibitor | WRN | Phase 2 | Colorectal Adenocarcinoma; Advanced Solid Tumors | May 2027 |
| VVD-159642 RAS-PI3Kα inhibitor | KRAS, PIK3CA | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| VVD-130037 | – | Phase 1 | Advanced Solid Tumors | Aug 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06004245 | VVD-133214 | Phase 1 | Advanced Solid Tumors | Oncology | May 2027 |
| NCT06804824 | VVD-159642 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT07811193 | VVD-133214 | Phase 2 | Colorectal Adenocarcinoma | Oncology | Jun 2028 |
| NCT05954312 | VVD-130037 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2030 |
Kumquat Biosciences Genfleet Therapeutics (Shanghai) Eikon Therapeutics iOnctura Erasca
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.